Biological insights from clinical trials with anti-TNF therapy

Springer Semin Immunopathol. 1998;20(1-2):211-28. doi: 10.1007/BF00832008.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibody Specificity
  • Arthritis, Rheumatoid / immunology
  • Arthritis, Rheumatoid / therapy*
  • Chemotaxis, Leukocyte
  • Clinical Trials as Topic
  • Cytokines / antagonists & inhibitors
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunoglobulin Heavy Chains*
  • Immunoglobulin gamma-Chains
  • Infliximab
  • Intercellular Adhesion Molecule-1 / blood
  • Leukocyte Count
  • Neovascularization, Pathologic / physiopathology
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Recombinant Fusion Proteins / therapeutic use
  • Selectins / blood
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / immunology*

Substances

  • Antibodies, Monoclonal
  • Cytokines
  • Immunoglobulin G
  • Immunoglobulin Heavy Chains
  • Immunoglobulin gamma-Chains
  • Receptors, Tumor Necrosis Factor
  • Recombinant Fusion Proteins
  • Selectins
  • Tumor Necrosis Factor-alpha
  • Intercellular Adhesion Molecule-1
  • Ro 45-2081
  • Infliximab
  • Etanercept